Aug 7, 2024 06:45AM
Jun 24, 2024 03:00AM
Jun 17, 2024 06:45AM
Jun 17, 2024 06:45AM
May 31, 2024 09:57AM
Feb 26, 2024 11:30PM
Dec 21, 2023 04:00PM Takeda Pharmaceutical (TAK) Announces China NMPA Approval of LIVTENCITY
Dec 21, 2023 04:00PM
Nov 9, 2023 03:50PM
Oct 3, 2023 04:50PM
Oct 2, 2023 04:35PM
Oct 2, 2023 04:30PM
Sep 25, 2023 08:45AM
Sep 25, 2023 08:44AM Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
May 25, 2023 04:31PM
Feb 2, 2023 05:40AM
Jan 11, 2023 08:37AM
Jan 11, 2023 08:36AM
Jan 5, 2023 06:46AM
Dec 19, 2022 02:30PM
Dec 8, 2022 06:45AM Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Nov 22, 2022 03:57PM
Nov 22, 2022 03:57PM
Nov 11, 2022 05:25AM
Nov 11, 2022 02:00AM
Oct 14, 2022 07:30AM
Aug 22, 2022 09:58AM
Aug 22, 2022 09:57AM Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Jun 9, 2022 05:10AM
Jun 9, 2022 04:30AM
Apr 22, 2022 08:04AM
Apr 22, 2022 08:00AM
Dec 8, 2021 07:02AM
Dec 8, 2021 07:00AM
Dec 2, 2021 09:49AM Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
Nov 23, 2021 05:26PM
Nov 23, 2021 05:24PM
Oct 8, 2021 05:41AM
Oct 7, 2021 06:15PM
Sep 15, 2021 04:41PM
Sep 15, 2021 04:40PM

64,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All